Amyris

Amyris, Inc. engages in the provision of bioscience solutions. It offers its products to the health and wellness, clean beauty, and flavor and fragrance markets. The company was founded by Jack D. Newman, Kinkead Keith Reiling, and Neil Renninger on July 17, 2003 and is headquartered in Emeryville, CA.

Earnings data Q1 2024

The principal business of Tara Gold Resources Corp. is the acquisition, exploration and development of high-quality precious metals projects with potential for economic commercial value. Tara Gold is currently focused on acquiring and developing properties in the natural resource belt of the Sierra Madre Occidental and other prolific areas in the states of Chihuahua, Sonora, and Sinaloa, Mexico.  Tara Gold provides investors growth exposure with a diversified exploration portfolio, multiple multi-million ounce targets and several near term production scenarios. Tara Gold owns equity positions in Cayden Resources Inc. (TSX-V: CYD) and Tara Minerals Corp. (TARM.OB), a public US company which explores and develops high-quality precious & non-precious metals and mineral projects in Mexico.

ChargePoint Holdings

Corteva Inc

This basket of industrial and electric vehicle stocks is primed to pole vault your portfolio.

3 Growth Stocks to Fuel Your 2022 Financial Freedom

OKLAHOMA CITY--(BUSINESS WIRE)-- #classaction--Federman & Sherwood Announces Certification of Securities Class Action Lawsuit Against Amyris, Inc.

Federman & Sherwood Announces Certification of Securities Class Action Lawsuit Against Amyris, Inc.

The days grew shorter last month, as did investors' patience with this synthetic-biology specialist.

Here's Why Amyris Stock Plunged 54% in November

Amyris is the only synthetic biology company developing and manufacturing a portfolio of products at scale. Amyris has obtained access to differentiated vaccine technology through a licensing arrangement with the Infectious Disease Research Institute.

Amyris: Vaccine Upside

EMERYVILLE, Calif., Nov. 23, 2021 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS) ("Amyris"), a leading synthetic biotechnology company accelerating the world to sustainable consumption through its Lab-to-Market™ operating platform, today announced that management will participate in a fireside chat at the Evercore ISI 4th Annual HealthCONx Conference on Wednesday, December 1 st at 3:30 pm ET.

Amyris To Present At The Evercore ISI 4th Annual HealthCONx Conference On December 1, 2021

Big Revenue miss for Q3 due to supply chain shortages and Amyris guides lower for Q4. Surprise $690 million convert is less dilutive (12%, not 18%) and at a beneficially higher effective conversion price ($15.90, not $10.75/share) due to a capped call hedge.

Amyris Buying Opportunity Created By Q3 Miss, Mega Convert And Potential Revolutionary COVID Vaccine

EMERYVILLE, Calif., Nov. 18, 2021 /PRNewswire/ -- Amyris, Inc., (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world to sustainable consumption through its Lab-to-Market™ operating platform, today announced that it will host a conference call and live webcast to discuss its recent financing activity on Monday, November 22, 2021 beginning at 6:00 a.m.

Amyris To Host Call Regarding Recent Financing Activity

EMERYVILLE, Calif., Nov. 15, 2021 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world to sustainable consumption through its Lab-to-MarketTM operating platform, announced that it has closed its offering of 1.50% convertible senior notes due 2026 (the "notes"), for gross proceeds of $690.0 million.

Amyris Closes Upsized Offering Of $690.0 Million Of 1.50% Convertible Senior Notes Due 2026

Amyris' synthetic biotechnology breakthrough with squalene. The real crown jewel of Amyris' current business segment.

Amyris: Valuations Are Attractive After Hype Around Synthetic Biotech Is Quelled By CEO's Ambitious Guidance

There's nothing artificial about the plunging price of this synthetic biology stock.

Why Shares of Amyris Are Plummeting This Week

EMERYVILLE, Calif., Nov. 10, 2021 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS) ("Amyris"), a leading synthetic biotechnology company accelerating the world to sustainable consumption through its Lab-to-MarketTM operating platform, today announced that it has priced $600.0 million aggregate principal amount of 1.50% convertible senior notes due 2026 (the "notes").

Amyris Prices $600.0 Million Of 1.50% Convertible Senior Notes Due 2026

Bears are turning their backs on this synbio stock today.

Why Shares of Amyris Are Getting Crushed Today

The stock price of Amyris Inc (NASDAQ: AMRS) fell over 30% during intraday trading today. This is why it happened.

Amyris (AMRS) Stock: Why The Price Substantially Fell Today

Amyris, Inc. (AMRS) CEO John Melo on Q3 2021 Results - Earnings Call Transcript

Amyris, Inc. (AMRS) delivered earnings and revenue surprises of -80.00% and -25.45%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Amyris, Inc. (AMRS) Reports Q3 Loss, Lags Revenue Estimates

EMERYVILLE, Calif., Nov. 8, 2021 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS) ("Amyris"), a leading synthetic biotechnology company accelerating the world to sustainable consumption through its Lab-to-Market™ operating platform, today announced that it proposes to offer $400.0 million aggregate principal amount of convertible senior notes due 2026 (the "notes"), subject to market conditions and other factors.

Amyris To Offer $400.0 Million Of Convertible Senior Notes Due 2026

ImmunityBio

EMERYVILLE, Calif., Nov. 8, 2021 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world to sustainable consumption through its Lab-to-MarketTM operating platform, today announced financial results for its third quarter ended September 30, 2021.

Amyris, Inc. Reports Third Quarter 2021 Financial Results

Amyris Inc (NASDAQ: AMRS) has entered into a 50:50 joint venture arrangement with ImmunityBio Inc (NASDAQ: IBRX) to commercialize a next-gen COVID-19 vaccine. The parties have signed a binding term sheet, and a definitive agreement is in process and is expected to be executed within the next month.

Amyris, ImmunityBio Join Forces For Next-Gen COVID-19 RNA Vaccine

EMERYVILLE, Calif., Nov. 8, 2021 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world to sustainable consumption through its Lab-to-MarketTM operating platform, today announced it has entered into a 50:50 joint venture arrangement with ImmunityBio, Inc. (Nasdaq: IBRX), a clinical-stage immunotherapy company, to accelerate the commercialization of a leading next-generation COVID-19 vaccine.

Amyris Announces JV Partnership With ImmunityBio For Next Generation COVID-19 RNA Vaccine

Amyris, a synthetic clean health and beauty biology company, is a key supplier of sustainable and natural ingredients and possesses some strong consumer brands too. Lack of market enthusiasm following the MG Empower deal points to investors having some doubts about financial capacity in view of the amount of cash in the balance sheet.

Amyris: Assessing Financial Capacity To Sustain Organic Growth, Carry COVID Research And Pay For Acquisition

Amyris, Inc. (AMRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amyris, Inc. (AMRS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

EMERYVILLE, Calif., Oct. 28, 2021 /PRNewswire/ -- Amyris, Inc., (Nasdaq: AMRS), a leading synthetic biotechnology company active in the Clean Health, Beauty and Wellness markets through its consumer brands and a top supplier of sustainable and natural ingredients, today announced that it will issue its financial results for the third quarter ended September 30, 2021 after the close of the financial markets on Monday, November 8, 2021.

Amyris to Host Third Quarter 2021 Financial Results Conference Call on November 8

Fulgent Genetics

Pacific Biosciences of California

The genomic revolution is upon us and these stocks could be great vehicles for investors who want to take advantage of it.

3 Genomics Stocks That Could Soar 60% or Better, According to Wall Street

Ocular Therapeutix

Renalytix AI plc

You can pick up small pieces of these great businesses for next to nothing.

News for Amyris Stock (AMRS)